CURE

Bladder Cancer Treatment Is Changing: What Patients Should Know

Flaig: It has been a remarkable 10 years for bladder cancer. If you think back to 10 or 15 years ago, we had no new ...
ascopubs.org

Impact of gene expression signatures of immune infiltration on response to sequential intravesical gemcitabine and docetaxel versus bacillus Calmette-Guerin in high-risk non ...

A non-coding RNA based classifier for favorable outcomes in clinically organ confined bladder cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract ...
ascopubs.org

Changes in circulating tumor cells (CTCs) and HER2 expression in evaluating the efficacy of neoadjuvant disitamab vedotin plus toripalimab treatment in patients with muscle ...

Clinical outcomes in metastatic bladder cancer associated with mutations in Trithorax-group protein genes. Discordance in HER2 expression in primary and recurrent/metastatic lesions of upper tract ...
Renal & Urology News

Neoadjuvant Disitamab Vedotin With Tislelizumab Shows Efficacy for HER2-Expressing MIBC

In a phase 1b-2 trial, neoadjuvant disitamab vedotin plus tislelizumab shows preliminary efficacy and acceptable toxicity in HER2-expressing muscle-invasive bladder cancer -- and may enable ...
Renal & Urology News

Part II: Current Treatment Options for Neurogenic Bladder Dysfunction

Noninvasive treatment options for NGB dysfunction include intermittent catheterization, Crede and Valsalva, indwelling catheterization, lifestyle changes/behavioral modification, and oral ...